Reverse Transcriptase Inhibitors
"Reverse Transcriptase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template.
| Descriptor ID |
D018894
|
| MeSH Number(s) |
D27.505.519.389.675.850 D27.505.954.122.388.077.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Reverse Transcriptase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Reverse Transcriptase Inhibitors".
This graph shows the total number of publications written about "Reverse Transcriptase Inhibitors" by people in this website by year, and whether "Reverse Transcriptase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 2 | 3 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Reverse Transcriptase Inhibitors" by people in Profiles.
-
Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS. 2010 Jul 17; 24(11):1657-65.
-
Utility of repeat genotypic resistance testing and clinical response in patients with three class resistance and virologic treatment failure. AIDS Patient Care STDS. 2007 Aug; 21(8):544-50.
-
Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007 Jan 01; 44(1):38-42.
-
A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Antivir Ther. 2007; 12(4):531-41.
-
Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients. AIDS. 2005 Oct 14; 19(15):1607-15.
-
Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfection. Clin Infect Dis. 2004 Aug 01; 39(3):402-10.
-
Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Acquir Immune Defic Syndr. 2004 Feb 01; 35(2):120-5.
-
Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr. 2003 Jun 01; 33(2):175-83.
-
Immune reconstitution after successful treatment with protease inhibitor-based and protease inhibitor-sparing antiretroviral regimens. J Acquir Immune Defic Syndr. 2002 Apr 15; 29(5):544-5.
-
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis. 2002 Mar 01; 185(5):599-607.